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OBJECTIVES: This study aims to conduct an assessment of reimbursement dossiers 
of orphan drugs in Belgium. First, a qualitative analysis reviews the evidence submitted 
in reimbursement dossiers of all orphan drugs. Second, an in-depth analysis compares 
the clinical evidence submitted to the European Medicines Agency with the Belgian 
reimbursement dossiers for selected orphan drugs. METHODS: A qualitative analysis 
examined all reimbursement dossiers of orphan drugs that have been submitted in 
Belgium between January 2002 and June 2008. The following information was 
extracted from each dossier: description of the orphan drug; indication; reimburse-
ment status; therapeutic value and needs; budget impact; and number of registered 
indications. For selected orphan drugs, an in-depth analysis extracted and compared 
information about the clinical trials, their primary endpoints and results from the 
following data sources: European Medicines Agency documents (i.e. the marketing 
authorization application ﬁ le, the European Public Assessment Report and the 
Summary of Product Characteristics); and the Belgian reimbursement dossiers. 
RESULTS: Reimbursement was awarded to the majority of orphan drugs. In addition 
to the ofﬁ cial criteria, other arguments such as the price, employment, patient popula-
tion, funding of diagnostic tests by the company seemed to play a role in the reimburse-
ment decision. Despite the low number of patients, randomized controlled trials were 
conducted for many orphan drugs. Budget impact analyses were simplistic and did 
not consider the impact across multiple indications. Also, some differences were 
observed in the clinical evidence submitted to the European Medicines Agency and 
the Belgian reimbursement authorities. CONCLUSIONS: There is substantial varia-
tion in the evidence that is submitted to the Belgian authorities in the context of an 
orphan drug reimbursement dossier. Also, some differences have been noted in the 
clinical evidence reported in European Medicines Agency documents and the evidence 
included in Belgian reimbursement dossiers of orphan drugs.
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OBJECTIVES: Our aim was to investigate whether efforts to develop innovative 
medicines in the European Union (EU) are focusing on the most relevant conditions 
from a global public health perspective. METHODS: We reviewed the information 
on new medicinal products approved by centralised procedure (from 1995 to 2009), 
available for the public in the European Commission Register of medicinal products 
and the European Public Assessment Reports (EPAR) from the European Medicines 
Agency. We included morbidity-mortality data for each disease group, according to 
the World Health Organization Global Burden of Disease project. We evaluated the 
association between authorised medicinal products and burden of disease measures 
(disability-adjusted life-years [DALYs]) in the EU and worldwide. RESULTS: We 
considered 520 marketing authorizations for medicinal products and 338 active ingre-
dients. New authorizations were seen to increase over the period analyzed. There was 
a positive, high correlation between DALYs and new medicinal products development 
(ρ = 0.619, P = 0.005) in the EU, that was moderate for middle-low income countries 
(ρ = 0.497, P = 0.030) and worldwide (ρ = 0.490, P = 0.033). In the EU, the most 
neglected conditions (related to their attributable health losses) were neuropsychiatric 
diseases, cardiovascular diseases, respiratory diseases, sense organ conditions or diges-
tive diseases, while globally they were perinatal conditions, respiratory infections, 
sense organ conditions, respiratory diseases, or digestive diseases. CONCLUSIONS: 
Our ﬁ ndings suggest that the development of new medicinal products is higher in some 
diseases than in others. Pharmaceutical industry and decision-makers are invited to 
consider the implications of this imbalance establishing work plans that allow for 
setting future priorities from a public health perspective.
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OBJECTIVES: The current variability in European health technology assessment and 
decision-making leads to uncertainty about how to measure efﬁ ciency and hampers 
adoption of new best-practice initiatives, such as the EUnetHTA Joint Action. In 
addition, such variability in organization makes comparison of the activities and 
outcomes of these systems problematic. The objective of this study was to develop a 
systematic process-mapping methodology to both clarify how these systems were 
organised and to enable comparison between the systems. METHODS: The process 
maps were designed from the point of view of the path that a new medicine takes 
from market authorization to market access. Key decision and evaluation gateways 
occurring within the process and key activities, such as provision of scientiﬁ c advice, 
were overlaid onto the process maps to further illuminate and contrast the different 
systems. RESULTS: The systems of eleven countries were mapped and common 
processes identiﬁ ed. Considerable differences in the systems were detected, including 
the extent of independence of appraisal, pricing and decision making bodies. However, 
despite differences in organization and sequence, the general path that a new medicine 
undertakes from registration to reimbursement was broadly similar. CONCLUSIONS: 
The process maps are a useful tool for the comparative visualization of the process of 
registration to reimbursement for new medicines. This methodology enables the iden-
tiﬁ cation of milestones that can be used to establish a benchmarking programme for 
the purpose of comparative performance evaluation between different countries. It is 
envisaged that benchmarking of HTA and decision-making agencies will lead to both 
process improvement and increased understanding of the costs and beneﬁ ts of making 
changes in the systems under evaluation—as has been the case for our previous activi-
ties benchmarking the drug regulatory authorities.
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OBJECTIVES: To describe the use of medications among Quebec (Canada) residents 
covered by private drug insurance and to compare with Quebec residents covered by 
the public drug insurance plan. METHODS: Persons aged less than 65 years with 
private drug insurance were recruited in community pharmacies and medical clinics 
between 2007 and 2010 and were included in a computerized registry called reMed. 
Patient’s identiﬁ cation, private drug plan information and socio-demographic vari-
ables were gathered at recruitment. Data related to prescriptions dispensed in com-
munity pharmacies are transferred to reMed bi-monthly from the community 
pharmacies’ computer services providers. We compared the 10 most prevalent medica-
tion classes dispensed (using the AHFS classiﬁ cation) and the average drug cost 
between reMed participants and Quebec residents covered by the public drug insur-
ance plan. RESULTS: In 2008, 2 211 reMed participants ﬁ lled at least one prescription 
in a community pharmacy. Participants were 43 years old on average, 31% were male, 
19% were current smokers and 46% were overweight or obese. In 2008, analgesics/
antipyretics, psychotherapeutic agents and antilipemic agents were the three most 
dispensed classes of medications among reMed participants and Quebec residents with 
public drug insurance. Despite that 8 of the 10 most prevalent classes of medications 
were in common between patients with public and private drug insurance, the average 
cost of medications was 22% lower among patients with public drug insurance 
($37.92 versus $46.42 per prescription). CONCLUSIONS: Patients with private and 
public drug insurance were found to have a similar distribution of medications dis-
pensed in community pharmacies. However, we found that patients covered by the 
public drug insurance plan paid on average their medications 22% less than patients 
covered by a private drug insurance plan.
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OBJECTIVES: ‘Real world’ data can improve understanding of the cost-effectiveness 
of health care technologies and are likely to become increasingly important in decisions 
affecting patient access and in drug development. However little is known about the 
investment industry currently makes in these studies, or their impact on HTA. The 
aim of this study was to examine industry views on the relevance and impact of ‘real 
world’ data on HTA and on the relative advantages and disadvantages of conducting 
these studies in the UK. METHODS: Survey of British pharmaceutical companies. 
RESULTS: Responses were received from 31 British pharmaceutical companies, cover-
ing most of the larger companies in terms of market share. Three quarters of these 
reported they were engaged in collecting real life data of some kind in the UK. Data 
collection efforts were more common for health service costs, resource use and treat-
ment pathways; clinical outcomes; burden of disease; and patient outcomes data. The 
collection of data on patients’ ability to work; patient costs; and impacts on patients’ 
caregivers/family was less common. The availability of local expertise on HTA was a 
leading factor in choosing to undertake such studies in the UK; other important factors 
were the perceived importance of local data to NICE; and the inﬂ uence of NICE on 
HTA decisions in other markets, particularly elsewhere in Europe. The main barrier 
to conducting studies in the UK was cost and perceived difﬁ culty in obtaining ethics 
consent and NHS approval. Views on whether ‘real world’ evidence inﬂ uenced NICE 
decisions were somewhat equivocal. However, participants felt that real world data 
were likely to be more important in providing evidence on health outcomes in chronic 
conditions, to track outcomes over longer time periods than is feasible in clinical trials, 
and for cancer and ‘orphan’ medicines. CONCLUSIONS: While industry recognises 
the value of ‘real world’ evidence, there are barriers to conducting such studies in the 
UK.
